Information Provided By:
Fly News Breaks for December 31, 2018
PTLA
Dec 31, 2018 | 16:24 EDT
William Blair analyst Matt Phipps says today's FDA approval of Portola Pharmaceuticals' generation 2 manufacturing for Andrexxa opens up a blockbuster opportunity for the company. The stock closed the trading day up 14% to $19.52. Phipps has an Outperform rating on Portola.
News For PTLA From the Last 2 Days
There are no results for your query PTLA